CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 12 enrolled
Drug / intervention
Aripiprazoledrug
Likely dose
Aripiprazole 2.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00420459
NCT00420459Phase 2Completed
CompareCT.gov

Aripiprazole in Fragile X Syndrome

Indiana University·interventional·Posted Jan 11, 2007·Updated Apr 18, 2017

In Brief

A Phase 2 clinical trial evaluating Aripiprazole for Fragile X Syndrome. Completed, enrolled 12 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the effectiveness and tolerability of aripiprazole in the treatment of children and adolescents with Fragile X Syndrome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFragile X Syndrome
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 11, 2007
Enrollment StartApr 1, 2007
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 19.5 years ago

Interventions

Aripiprazoledrug

All subjects will initially receive 2.5 mg/day of aripiprazole during the first week. The dosage may be increased to a maximum of 20 mg/day over 8 weeks.